News and Resources
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)
Discover this News
Biohaven Acquires Kv7 Ion Channel Platform For The Treatment Of Epilepsy And Other Neurologic Disorders From Channel Biosciences, A Subsidiary Of Knopp Biosciences
Discover this News
Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain
Discover this News
Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function
Discover this News
Crafting a Cure for Diabetic Neuropathic Pain, Molecule by Molecule (Published by NIH)
Discover this News
Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
Discover this News
Knopp Biosciences Appoints Stephen E. Butts to Board of Managers
Discover this News
Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference
Discover this News
Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer
Discover this News
1
2